An FDA-approved PARP inhibitor TEST FOR BRCA m * If indicated, If she has ovarian cancer, TREAT WITH LYNPARZA 1 PARP=poly (ADP-ribose) polymerase. *Test patients with ovarian cancer for germline BRCA mutations ( BRCA m). INDICATION LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA -mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon veriﬁ cation and description of clinical beneﬁ t in conﬁ rmatory trials. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS There are no contraindications for LYNPARZA. Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in <1% of patients treated with LYNPARZA, and the majority of those reports were fatal. The duration of therapy in patients who developed secondary MDS/AML varied from <6 months to >2 years. In a randomized placebo-controlled trial, MDS/AML occurred in 2% of patients treated with LYNPARZA. All of these patients had previous chemotherapy with platinum agents and/or other DNA damaging agents, including radiotherapy, and some of these patients also had a history of previous cancer or of bone marrow dysplasia. Please see the following pages for additional Important Safety Information and accompanying Brief Summary of Prescribing Information.